Tocagen

Recurrent brain cancer represents a very high unmet medical need and patients with this disease have very few treatment options, said Marty Duvall, chief executive officer of Tocagen. While the Toca 5 trial results are disappointing, we will be conducting a thorough analysis of the data including molecular analyses and pre-planned subgroups. In addition, we will be conducting an operational review. We sincerely appreciate the exceptional support from patients and their families as well as patient advocates, physicians and our employees who have been committed to the rigorous study of Toca 511 & Toca FC in the Toca 5 trial.

On July 17, we observed the inaugural Glioblastoma Awareness Day with an open house event. We were honored to be joined by patients, advocates, politicians and physicians. Tune in to our new video to see what all we did. #braincancer #honorandact #glioblastoma

Almost every cell in the bulk of a brain tumor is different, or heterogeneous. This means that it is unlikely that any single agent will be able to destroy the bulk of the cells. In addition, these tumors change over time, so without additional biopsies, we’re treating the wrong target. This speaks to the need to engage the immune system in high grade glioma. Watch the recent Future of Glioma video for details: https://www.youtube.com/watch?v=d80FszrC4Xk #braincancer #braintumor #glioma

We commemorated Glioblastoma Awareness Day today alongside patients, caregivers, dignitaries and advocacy groups. Just one of the several moving stories shared today was from Greg Labancz, a patient who was told he had 2 years to live. He’s been alive for 6 years now. #GBMDay #braincancer #HonorAndAct

To commemorate Glioblastoma Awareness Day this Wednesday, Future of Glioma will host a podcast featuring the industry’s leading #oncology experts. Have any questions? Submit them here and we’ll try to answer during the podcast. Stay tuned for audio download info! #HonorAndAct #GBMDay #braincancer https://bit.ly/32sc6HI

We’re so glad the United States Senate took action to officially designate July 17 as Glioblastoma Awareness Day! The resolution is aimed at generating public awareness for #glioblastoma (GBM), the most common and aggressive form of brain cancer and leveraging support for research, treatment development, patients and their families. #HonorAndAct #GBMDay #braincancer

The tumor microenvironment can suppress the immune system and allow high grade #glioma to proliferate. Overcoming the challenges posed by this immune suppression may play a key role in addressing unmet needs in the treatment of high grade glioma. Learn more: https://bit.ly/2LwRCHI #braincancer

80% of high grade #glioma recurrences occur within the prior treatment field. This indicates that the tumor microenvironment can support the growth and invasion of tumors. A better understanding of this environment may lead to new treatment strategies. Learn more by watching this video https://bit.ly/2FCGB3T and visiting www.futureofglioma.com. #braincancer #glioblastoma

Hear from University of Washington, UC San Diego and University of Minnesota experts in neuro-oncology on the current landscape in high grade glioma. In this video, they discuss the importance of understanding the mechanism of the disease and seeking new approaches for #braincancer patients. https://bit.ly/2Y9I8pf #glioblastoma

Last night, the TOCA team won fastest #biotech company in the San Diego 5K Corporate Dash! The Corporate Dash promotes healthy living and teamwork, while also benefiting the Challenged Athletes Foundation. #CorporateDash

The TOCA team is rooting for the USA Women's Soccer Team and celebrating with a large rice krispie treat! #fifawomensworldcup #FIFA19

We launched Future of Glioma to paint a better picture of high grade #glioma. To hear from experts on treating and understanding the disease, follow us on Twitter @FutureofGlioma and visit our site www.futureofglioma.com. #braincancer

We are encouraged by the recommendation from the IDMC to continue the Toca 5 trial without modification and are looking forward to reporting the final analysis of the Toca 5 trial by the end of the year, said Marty J Duvall, our CEO. Press release: https://bit.ly/2JVK6Fm #braincancer